Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 9:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 445 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: GLP 1 Clear all

Conditions: Chronic Kidney Disease, Type 2 Diabetes
Interventions: Finerenone, Semaglutide, Lotensin, Capoten, Enalapril, Monopril, Lisinopril, Univasc, Aceon, Accupril, Altace, Mavik, Edarbi, Atacand, Avapro, Cozaar, Benicar, Micardis, Diovan, Invokana, Farxiga, Jardiance, Ertugliflozin, Brenzavvy, Sotagliflozin; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 84 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Diabetes Mellitus, Type 2, Heart Failure, Diastolic
Interventions: Exenatide; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 30 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Overweight, Obesity
Interventions: NNC0174-0833, Placebo (NNC0174-0833), Liraglutide 3.0 mg, Placebo (Liraglutide 3.0 mg); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 706 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 22
States / cities: Anaheim, California • Spring Valley, California • Crystal River, Florida + 19 more

Conditions: Diabetes, Effects of Liraglutide Administration on Brain Activity, Weight Loss, Hunger
Interventions: Liraglutide, Placebo; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Spinal Cord Injuries, Insulin Resistance, Pre Diabetes, Obesity
Interventions: Semaglutide 1MG Injection [Ozempic], No Intervention; Drug · Other
Lead sponsor: James J. Peters Veterans Affairs Medical Center; Federal
Eligibility: 18 Years to 69 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: semaglutide, liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 706 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 84
States / cities: Birmingham, Alabama • Coronado, California • Lancaster, California + 71 more

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: NNC0114-0006, liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 13
States / cities: La Jolla, California • Northridge, California • Aurora, Colorado + 10 more

Conditions: Diabetes Mellitus, Non-Insulin-Dependent
Interventions: NNC 90-1170; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 30 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Post Bariatric Hypoglycemia
Interventions: Avexitide, Placebo; Drug · Other
Lead sponsor: Amylyx Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 21
States / cities: Stanford, California • Aurora, Colorado • Jacksonville, Florida + 16 more

Conditions: Hypoglycemia, Diabetes Mellitus, Type 1
Interventions: dasiglucagon, GlucaGen; Drug
Lead sponsor: Zealand Pharma; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Orlando, Florida • Meridian, Idaho

Conditions: Obesity, Breast Cancer Risk
Interventions: tirzepatide; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 40 Years to 64 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Kansas City, Kansas • Westwood, Kansas

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, Exenatide, Dapagliflozin, Exenatide and Dapagliflozin; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 70 Years
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Severe Obesity, Obesity, BMI Greater Than 30
Interventions: Tirzepatide, Standard of Care post-gastric bypass; Drug · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 25 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity, TIPS
Interventions: Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect), Lifestyle Counseling - Diet & Physical-Activity Program; Procedure · Drug · Behavioral
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome, Impaired Glucose Tolerance, Disorder of Glucose Regulation
Interventions: Metformin XR plus placebo, Metformin XR plus liraglutide; Drug
Lead sponsor: Woman's; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 153 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, sitagliptin, metformin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 665 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 60
States / cities: Birmingham, Alabama • Escondido, California • Fresno, California + 54 more

Conditions: Insulin Resistance
Interventions: Liraglutide, Sugar Pill; Drug
Lead sponsor: Phoenix VA Health Care System; Federal
Eligibility: 40 Years to 75 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, sitagliptin, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 58
States / cities: Phoenix, Arizona • Tucson, Arizona • Escondido, California + 46 more

Conditions: Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
Interventions: Tirzepatide, Placebo; Drug · Other
Lead sponsor: T. John Winhusen, PhD; Other
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 6 more

Conditions: Heart Disease
Interventions: Exendin-9, GLP-1, saline; Drug · Other
Lead sponsor: David Dalessio; Other
Eligibility: 40 Years to 60 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Obesity, Metabolic Disease
Interventions: Standard Care, Culturally-tailored dietary and behavioral intensive lifestyle intervention, Placebo, Tirzepatide; Behavioral · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 21 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Obesity, Overweight
Interventions: VRB-101, Placebo; Drug
Lead sponsor: Verdiva Bio Dev Limited; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 22
States / cities: Anniston, Alabama • Cullman, Alabama • Phoenix, Arizona + 18 more

Conditions: Pulmonary Aspiration
Interventions: Gastric ultrasound; Diagnostic Test
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Obesity
Interventions: Liraglutide, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Orlando, Florida

Search by objective public record fields.

Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart Failure

Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.

Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI

Once Weekly GLP-1 in Persons With Spinal Cord Injury

Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes

A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function

NNC 90-1170 Mechanism of Action: A Double-Blind, Randomized, Single-Center, Placebo-Controlled, Crossover Study to Examine Beta-Cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes

Avexitide for Treatment of Post-Bariatric Hypoglycemia

A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus

Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers

Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria

GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial

Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease

Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)

The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus

The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans

Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

Effect of GLP-1 on Postprandial Lipid Metabolism

Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity

A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Gastric Ultrasound Assessment for Preoperative Prandial State of Patients Taking Glucagon-Like Peptide-1 Receptor Agonists

Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects